Article Text

other Versions

PDF
Extended report
Psoriatic arthritis treatment and the risk of herpes zoster
  1. D Zisman1,2,
  2. H Bitterman2,3,
  3. G Shalom3,
  4. I Feldhamer3,
  5. D Comanesther3,
  6. E Batat3,
  7. S Greenberg-Dotan3,
  8. S Cohen1,
  9. A D Cohen3,4
  1. 1Department of Rheumatology, Carmel Medical Center, Haifa, Israel
  2. 2The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel
  3. 3Chief Physician's Office Central Headquarters, Clalit Health Services, Tel Aviv, Israel
  4. 4Faculty of Health Sciences, Siaal Research Center for Family Medicine and Primary Care, Ben-Gurion University of the Negev, Beer-Sheva, Israel
  1. Correspondence to Dr Devy Zisman, Department of Rheumatology, Carmel Medical Center, 7 Michal Street, Haifa 34362, Israel; devyzisman{at}gmail.com

Abstract

Objectives To study the association between traditional disease-modifying antirheumatic drugs (c-DMARD) or anti-TNF-α agents and herpes zoster (HZ) in patients with psoriatic arthritis (PsA).

Methods A retrospective cohort study was conducted in patients with PsA between 2002 and 2013. Patients were grouped as follows: no DMARDs (Group A); c-DMARDs (Group B); anti-TNF-α agents (Group C); anti-TNF-α agents in combination with c-DMARDs (Group D). Crude incidence rates (IR) were calculated as number of HZ episodes per 1000 patient-years. A Cox regression model was used to adjust for HZ risk factors (age, gender, steroid use, Charlson Comorbidity Index score, and previous treatment) in order to estimate their contribution to the risk of the first HZ event.

Results The study included 3128 patients, mean age 50.26±14.54 years; 46.2% male. During a period of 20 096 person-years 182 HZ events were observed. The crude IR (95% CI) of HZ in the study population was 9.06 per 1000 patient-years, and in Groups A-D 7.36 (5.41 to 9.79), 9.21 (7.5 to 11.21), 8.64 (4.84 to 14.26), 17.86 (10.91 to 27.58), respectively. In a multivariate analysis, age (HR 1.01, 95% CI 1.00 to 1.02), treatment with steroids (HR 1.08, 95% CI 1.04 to 1.13), and a combination of anti-TNF-α agents and c-DMARDs (HR 2.37, 95% CI 1.32 to 4.22) were significantly associated with HZ events.

Conclusions In our database, the risk of HZ was significantly increased with age, treatment with steroids, and combination of anti-TNF-α agents and c-DMARDs, but not with c-DMARDs or anti-TNF-α therapy alone. Time to HZ event was shorter in patients treated with anti -TNF-α agents.

  • Anti-TNF
  • Psoriatic Arthritis
  • Treatment

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.